Rigel Q4 net income $0.7M; TAVALISSE sales $25.7M (+17% YoY); acquires GAVRETO rights

RIGEL PHARMACEUTICALS INC

Q4 total revenue $35.8M, TAVALISSE net sales $25.7M (+17% YoY), REZLIDHIA net sales $3.9M (+333% YoY).
FY 2023 net loss $25.1M ($0.14/sh) vs $58.6M in 2022; revenue $116.9M, TAVALISSE $93.7M (+24% YoY).
Acquired U.S. rights to GAVRETO (pralsetinib) for RET+ NSCLC/thyroid cancer; expects sales recognition in Q3 2024.
Q4 TAVALISSE bottles shipped to patients/clinics: 2,463; REZLIDHIA bottles: 278 direct, QoQ growth 47%.
Cash & short-term investments $56.9M at Dec 31, 2023, vs $58.2M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 5, 2024, Rigel Pharmaceuticals, Inc. (“ Rigel ”) announced certain financial results for its fourth quarter and year ended December 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-031010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.